Beijing Jiyuan Biotechnology

Beijing Jiyuan Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of regenerative medicine and stem cell therapies. The company focuses on utilizing human umbilical cord mesenchymal stem cells (hUC-MSCs) to treat a variety of chronic and degenerative conditions, including premature ovarian failure, liver cirrhosis, and knee osteoarthritis. Jiyuan Biotech operates a comprehensive platform that spans from basic research and cell banking to clinical application and industrialization. Their lead programs are currently in Phase 1 and Phase 2 clinical trials in China, aiming to address significant unmet medical needs in the field of regenerative medicine. The company maintains a state-of-the-art R&D center and a GMP-compliant manufacturing facility to support its clinical pipeline. Through collaborations with leading hospitals and research institutions, Jiyuan Biotech is advancing the standardization and clinical translation of cell-based medicines.